Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wellbeing Digital Sciences Inc (OP: KONEF )

N/A UNCHANGED
Last Price Updated: 3:57 PM EST, Mar 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Wellbeing Digital Sciences Inc

< Previous 1 2 Next >
World's Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees
The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gathered over 12,000 people from the entire psy 
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License
A Contract Research Organization (CRO) and a wholly-owned subsidiary of Wellbeing Digital Sciences Inc. 
Via Benzinga
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established... 
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Wellbeing Digital Net Loss Continues To Grow: Q2 Reaches $5.15M, Up By 552% YoY
Wellbeing Digital Sciences Inc. (OTCQB:KONEF 
Via Benzinga
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a... 
Via Benzinga
Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers
In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council. 
Via Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a... 
Via Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc. 
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science... 
Via Benzinga
Successful Study On Transdermal CBD & THC Delivery Presents Benefits For Treating Chronic Conditions
Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company announced that its wholl 
Via Benzinga
Psyched: Top Psychedelics Execs., 50% Of Americans Support Medical Psychedelics, Cary Grant's LSD Therapy & More
15 Global Psychedelics Executives To Keep An Eye On In 2022 
Via Benzinga
Pathway Health To Acquire IRP Health From Wellbeing Digital Sciences
Wellbeing Digital Sciences Inc. 
Via Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy 
Via Benzinga
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Being the sole psychedelic legally available as medicine, ketamine-assisted therapy services are expanding at a rapid pace across the U.S.  
Via Benzinga
Wellbeing Digital Reports 4Q Finances, 'Three Key Pillars' Stay Strong
Wellbeing Digital Sciences Inc. (OTC: KONEF) filed its financial results for the quarter ended July 31, 2022 and provided some insight on their most recent businesses. Numbers for the selected period... 
Via Benzinga
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
KGK Sciences Inc., a subsidiary company of psychedelics healthcare researcher and provider Wellbeing Digital Sciences Inc. 
Via Benzinga
Wellbeing Digital Introduces Women In Psychedelics, A Network For Female Minds In Psychedelics
Mental healthcare company Wellbeing Digital Sciences Inc. (OTC: KONEF) and its subsidiary KGK Science Inc. are the founding sponsors of the Women in Psychedelics Network, also known as “WIP.” 
Via Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ: 
Via Benzinga
Wellbeing Digital, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Wellbeing Digital (OTC: 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 7, 2022
GAINERS: GH Research (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 4, 2022
GAINERS: Wellbeing Digital (OTC: 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 1, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2022
GAINERS: Wellbeing Digital (OTC: 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 14, 2022
GAINERS: Wellbeing Digital (OTC: 
Via Benzinga
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.